Bell Investment Advisors’s NovoCure NVCR Stock Holding History

Bell Investment Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-36	Closed	-$563	–	1959
2024 Q1	$563	Hold	36	–	–	﹤0.01%	1781
2023 Q4	$538	Buy	36 +21	+140%	+$281	﹤0.01%	1805
2023 Q3	$243	Sell	15 -6	-29%	-$173	﹤0.01%	1895
2023 Q2	$872	Hold	21	–	–	﹤0.01%	1632
2023 Q1	$1.26K	Sell	21 -15	-42%	-$1.2K	﹤0.01%	1469
2022 Q4	$2.64K	Hold	36	–	–	﹤0.01%	1140
2022 Q3	$3K	Hold	36	–	–	﹤0.01%	956
2022 Q2	$3K	Buy	+36	New	+$2.71K	﹤0.01%	989
2021 Q4	$3K	Buy	37 +13	+54%	+$1.3K	﹤0.01%	1014
2021 Q3	$3K	Buy	+24	New	+$3.63K	﹤0.01%	951

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bell Investment Advisors's NVCR Position: Q2 2024 in Review

Bell Investment Advisors sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 36 shares — an estimated $563 sold.

Bell Investment Advisors first reported a position in NVCR in Q3 2021 and held it in 10 quarters. The position peaked at $3K in Q3 2022. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

Bell Investment Advisors reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
Bell Investment Advisors sold 36 NovoCure shares in Q2 2024, an estimated $563.
Bell Investment Advisors first reported a position in NovoCure in Q3 2021 and held it in 10 quarters.
Bell Investment Advisors's NovoCure position peaked at $3K in Q3 2022.
236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Bell Investment Advisors's 13F filing for Q2 2024, filed 8 Aug 2024.